Compare Dynatrace Inc. Common Stock (DT) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dynatrace Inc. Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Dynatrace Inc. Common Stock trades at $64.1 (market cap $18.63B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Dynatrace Inc. Common Stock is far larger — about 19.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Dynatrace Inc. Common Stock is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dynatrace Inc. Common Stock for 3 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| DT | MRVI | |
|---|---|---|
Market Cap | $18.63B | $977.37M |
Volume | 8,438,411 | 2,742,564 |
Sector | Technology | Health |
52-Week High | $65.25 | $9.00 |
52-Week Low | $32.36 | $2.83 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $17.68B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dynatrace (DT) trades at $64.46, down 1.21% on the day, with a bullish technical outlook supported by moving averages and strong institutional interest. The company reported robust revenue growth to $1.70B in 2025 and has consistently beaten earnings estimates, though its valuation ratios like a P/E of 128.94 are elevated. Recent developments include achieving FedRAMP certification and completing the acquisition of Arize, enhancing its AI observability platform.
The outlook is positive given strong analyst support (85.71% buy ratings) and a consensus price target of $62.44, though risks include high valuation sensitivity and projected net income decline in 2026. Earnings growth and federal market expansion are key catalysts, but investors should monitor execution against lofty expectations.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dynatrace Inc. Common Stock
Dynatrace provides an observability, security, and automation platform for cloud and IT environments. Its platform integrates data such as logs, metrics, and traces to help organizations monitor digital systems.
Read more on DT →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
